Zacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) to Post -$0.18 EPS

Wall Street analysts forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will announce earnings of ($0.18) per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Ironwood Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.22). Ironwood Pharmaceuticals reported earnings per share of ($0.12) during the same quarter last year, which would suggest a negative year over year growth rate of 50%. The firm is scheduled to report its next earnings report on Tuesday, February 20th.

According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($1.08) per share for the current year, with EPS estimates ranging from ($1.15) to ($1.03). For the next financial year, analysts forecast that the firm will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.61) to ($0.32). Zacks’ EPS averages are an average based on a survey of analysts that cover Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.18) EPS.

Several brokerages recently commented on IRWD. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. Mizuho lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $20.00 to $16.00 in a report on Wednesday, December 6th. Credit Suisse Group began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 price target for the company. Finally, Bank of America lowered shares of Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and cut their price target for the stock from $20.00 to $15.00 in a report on Friday, January 5th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $17.56.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 60,000 shares of Ironwood Pharmaceuticals stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total transaction of $927,000.00. Following the sale, the insider now owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the sale, the chief executive officer now directly owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 175,769 shares of company stock worth $2,679,491. 7.63% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Fisher Asset Management LLC boosted its stake in Ironwood Pharmaceuticals by 43.8% during the 4th quarter. Fisher Asset Management LLC now owns 289,214 shares of the biotechnology company’s stock worth $4,335,000 after purchasing an additional 88,155 shares during the last quarter. Sawyer & Company Inc acquired a new stake in Ironwood Pharmaceuticals during the 4th quarter worth $615,000. Public Employees Retirement System of Ohio boosted its stake in Ironwood Pharmaceuticals by 4.8% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 120,888 shares of the biotechnology company’s stock worth $1,906,000 after purchasing an additional 5,513 shares during the last quarter. California Public Employees Retirement System boosted its stake in Ironwood Pharmaceuticals by 7.1% during the 3rd quarter. California Public Employees Retirement System now owns 246,617 shares of the biotechnology company’s stock worth $3,889,000 after purchasing an additional 16,417 shares during the last quarter. Finally, Granahan Investment Management Inc. MA boosted its stake in Ironwood Pharmaceuticals by 24.5% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 436,000 shares of the biotechnology company’s stock worth $6,876,000 after purchasing an additional 85,904 shares during the last quarter.

Shares of Ironwood Pharmaceuticals (IRWD) traded up $0.50 during midday trading on Friday, reaching $16.28. 2,635,307 shares of the company traded hands, compared to its average volume of 1,815,709. The stock has a market cap of $2,363.13, a price-to-earnings ratio of -16.78 and a beta of 1.45. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. Ironwood Pharmaceuticals has a 12 month low of $13.43 and a 12 month high of $19.94.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/27/zacks-analysts-expect-ironwood-pharmaceuticals-inc-irwd-to-post-0-18-eps.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply